Acolbifene
- Generic Name
- Acolbifene
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31NO4
- CAS Number
- 182167-02-8
- Unique Ingredient Identifier
- 815LJ9X0D1
- Background
Acolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ
- Interventions
- Procedure: Biospecimen CollectionProcedure: MammographyOther: Questionnaire AdministrationProcedure: Random Periareolar Fine-Needle Aspiration
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT05941520
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00853996
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath